Displaying drugs 14626 - 14650 of 15275 in total
Cambendazole
Experimental
Vet approved
Pictilisib
Pictilisib has been used in trials studying the treatment of Solid Cancers, Breast Cancer, Advanced Solid Tumours, Metastatic Breast Cancer, and Non-Hodgkin's Lymphoma, Solid Cancers, among others.
Investigational
Matched Description: … studying the treatment of Solid Cancers, Breast Cancer, Advanced Solid Tumours, Metastatic Breast Cancer, and …
Adriforant
Adriforant is under investigation in clinical trial NCT00992342 (A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers).
Investigational
Matched Description: … Adriforant is under investigation in clinical trial NCT00992342 (A Phase 1 Study To Evaluate The Safety And …
Hymenialdisine
Experimental
6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE
Experimental
2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE
Experimental
Brostallicin
Investigational
OMS-103HP
OMS103HP is the first drug being developed to improve joint function following arthroscopic surgery, one of the most common procedures performed today by orthopedic surgeons.
Investigational
OSI-461
OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).
Investigational
Ralmitaront
Ralmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder).
Investigational
Matched Description: … Ralmitaront is under investigation in clinical trial NCT04512066 (A Trial of the Efficacy and the Safety …
Pro-Pro-Thr-Val-Pro-Thr-Arg
Investigational
Matched Iupac: … pyrrolidin-2-yl]formamido}butanamido]-3-methylbutanoyl]pyrrolidin-2-yl]formamido}butanamido]pentanoic acid …
CX157
CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A inhibitors of this class.
Investigational
Matched Description: … dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and …
Ulixertinib
Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity . It is currently in clinical trials for the treatment of a wide range of tumors.
Investigational
Matched Description: … Ulixertinib is a a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and ERK1/2 selectivity …
Serabelisib
Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants).
Investigational
Matched Description: … investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and …
ABT-072
ABT-072 is under investigation in clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C).
Investigational
Matched Description: … clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and …
2X-121
2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP).
Investigational
Matched Description: … 2X-121 is under investigation in clinical trial NCT03562832 (Investigation of Anti-tumour Effect and …
Pyrithiamine Pyrophosphate
Experimental
3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
Experimental
Displaying drugs 14626 - 14650 of 15275 in total